{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-012020","form_type":"8-K","ticker":"ABT","cik":"0000001800","company_name":"ABBOTT LABORATORIES","filed_at":"2023-04-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.653503+00:00","generated_at":"2026-06-16T23:49:33.361123+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Abbott Q1 revenue $9.7B, adj EPS $1.03; base business organic growth 10.0%","bullets":["Q1 GAAP EPS $0.75; adjusted EPS $1.03; revenue $9.747B, down 18.1% reported, but organic base business up 10.0%.","Full-year 2023 adjusted EPS guidance unchanged at $4.30-$4.50; COVID testing-related sales forecast ~$1.5B.","Medical Devices organic sales grew 12.4%; FreeStyle Libre sales $1.2B with ~50% U.S. growth.","Nutrition organic sales up 10.3% (Pediatric +18.4% organic); Diagnostics ex-COVID tests organic +4.4%.","Dividend of $0.51/share declared, payable May 15; 51 consecutive years of dividend increases."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-012020","json":"https://secwatch.observer/filing/0001628280-23-012020.json","markdown":"https://secwatch.observer/filing/0001628280-23-012020.md","text":"https://secwatch.observer/filing/0001628280-23-012020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800/000162828023012020/0001628280-23-012020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800/000162828023012020/abt-20230419.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T23:49:33.361123+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cb063ce5b2be79836988845cb4b3ade6cb84a2b0","claim":"ABBOTT LABORATORIES reported first quarter ended March 31, 2023 results: revenue $9.7 billion, EPS First-quarter GAAP diluted EPS of $0.75 and adjusted diluted EPS of $1.03. Guidance reaffirmed.","evidence_excerpt":"in accordance with GAAP. --- EX-99.1 (EX-99.1) --- 9.1 News Release Abbott Reports First-Quarter 2023 Results; Increases Outlook For Underlying Base Business – Sales of $9.7 billion driven by strong underlying base business performance – Reported sales decreased 18.1 percent due to anticipated decline in COVID-19 testing-related sales versus prior year –","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828023012020/0001628280-23-012020-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$9.7 billion"},{"label":"EPS","value":"First-quarter GAAP diluted EPS of $0.75 and adjusted diluted EPS of $1.03"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}